Actively Recruiting
GRID Therapy for Extremity Soft Tissue Sarcoma
Led by UNC Lineberger Comprehensive Cancer Center · Updated on 2025-10-20
20
Participants Needed
1
Research Sites
144 weeks
Total Duration
On this page
Sponsors
U
UNC Lineberger Comprehensive Cancer Center
Lead Sponsor
R
Radiation Oncology Institute
Collaborating Sponsor
AI-Summary
What this Trial Is About
Patients with extremity soft tissue sarcoma (STS) are at high risk of recurrence. Pre-operative radiotherapy is used to increase the safe removal of tumors and improve local control in these patients. Increasing the preoperative radiotherapy dose with standard techniques might lead to normal tissue toxicity and postoperative wound complications. GRID radiation therapy is a technique that may increases radiation dose with minimal added toxicity. It is hypothesized that GRID radiation dose will improve tumor response without increasing post-operative wound complications. While GRID has been used in many patients, there have been few formal studies to evaluate the safety and efficacy of the technique. In this study, a single priming dose of GRID will be administered to subjects with high-risk extremity soft tissue sarcoma prior to standard radiotherapy and tumor resection to determine the safety and clinical efficacy of the GRID dose. This single-arm pilot study will assess the safety of spatially fractionated grid radiation therapy (GRID) on 20 subjects with resectable extremity soft tissue sarcoma, followed by standard-of-care conventional radiotherapy (XRT) and tumor resection.
CONDITIONS
Official Title
GRID Therapy for Extremity Soft Tissue Sarcoma
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Provided written informed consent and HIPAA authorization
- Age 18 years or older at consent
- ECOG Performance Status of 0 to 2 (or Karnofsky score 50 to 100)
- Confirmed diagnosis of extremity soft tissue sarcoma by biopsy
- If prior surgery for presumed benign condition, at least 5 cm of tumor remains without complete resection
You will not qualify if you...
- Prior radiotherapy to the tumor site
- Complete tumor removal or tumor recurrence after surgery
- Serious or non-healing wound, ulcer, or bone fracture in the treatment limb within 5 years
- Clinically significant lymphedema in the treated limb
- History of lupus, scleroderma, Sjogren's syndrome, Ehlers-Danlos syndrome, or other collagen vascular disease with increased radiation risk
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
University of North Carolina at Chapel Hill, Department of Radiation Oncology
Chapel Hill, North Carolina, United States, 27599
Actively Recruiting
Research Team
E
Erin Jennings
CONTACT
C
Claire Kowalczyk
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here